Current Report Filing (8-k)
November 15 2018 - 7:12AM
Edgar (US Regulatory)
U.S.
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): November 15, 2018
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
001-36268
|
|
22-2983783
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(I.R.S.
Employer
|
incorporation
or organization)
|
|
File
Number)
|
|
Identification
Number)
|
201
Grove Road
Thorofare,
New Jersey USA 08086
(Address
of principal executive offices, including zip code)
(856)
848-8698
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
2.02
|
Results
of Operations and Financial Condition.
|
On
November 15, 2018, Akers Biosciences, Inc. (the “Company”) issued a press release announcing the financial results
and operational highlights for the third quarter 2018. A copy of the press release is furnished as Exhibit 99.1 to this current
report on Form 8-K.
In
accordance with General Instruction B.2 of Form 8-K, the information furnished pursuant to this Item in this Current Report on
Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be incorporated
by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except
to the extent the Company specifically states that such information is to be considered “filed,” including in any
such registration statement or other document.
Item
9.01
|
Financial
Statements and Exhibits.
|
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
|
Date:
November 15, 2018
|
By:
|
/s/
Howard R. Yeaton
|
|
|
Howard
R. Yeaton
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Sep 2023 to Sep 2024